Placebo News and Research

RSS

Flunisyn Phase 2a trial data shows positive results in elderly population

Following the widely publicised US Centers for Disease Control and Prevention report in February that the current season's flu vaccine is only 9% effective in the over-65 population, Immune Targeting Systems Limited, today announces positive data from a Phase 2a trial with the Company's lead pan-strain influenza A T-cell vaccine, Flunisyn, in the elderly population.

17 Apr 2013

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

GlycoMimetics, Inc. today announced top line clinical results from a Phase 2 study of GMI-1070 in patients experiencing vaso-occlusive crisis of sickle cell disease.

17 Apr 2013

COPD phase III study by Almirall and Forest Laboratories announces positive results

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

16 Apr 2013

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility.

16 Apr 2013

GTx to continue two pivotal Phase III clinical trials of enobosarm

GTx, Inc. today announced that a per protocol safety review of unblinded safety data on Friday April 12, 2013, by an independent Data Safety Monitoring Board, resulted in a determination that GTx continue as planned its two pivotal Phase III clinical trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer.

16 Apr 2013

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

16 Apr 2013

L-carnitine improves cardiac health in patients after heart attack, say researchers

L-carnitine significantly improves cardiac health in patients after a heart attack, say a multicenter team of investigators in a study published today in Mayo Clinic Proceedings.

15 Apr 2013

KYTHERA Biopharmaceuticals reports positive results from Phase IIb study of ATX-101

KYTHERA Biopharmaceuticals, Inc. today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat, commonly known as double chin, during an oral session at The Aesthetic Meeting 2013, organized by the American Society for Aesthetic Plastic Surgery, April 11-16, New York, NY.

15 Apr 2013

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

The Massachusetts General Hospital Neurological Clinical Research Institute and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis, received a Best Practices Award at the 2013 Bio-IT World Conference & Expo.

15 Apr 2013

Two physicians receive Junior Investigator Recognition Awards at Internal Medicine 2013

Annals of Internal Medicine and the American College of Physicians will honor Adrienne Allen, MD, MPH and Matthew Spitzer, MD with the Junior Investigator Recognition Awards at Internal Medicine 2013, the annual scientific meeting of the American College of Physicians.

15 Apr 2013

Dexmedetomidine may be an effective treatment option for opioid-induced hyperalgesia

Surgical patients who demonstrated heightened pain sensitivity, or hyperalgesia, induced by high doses of a synthetic opioid had their symptoms alleviated by co-treatment with dexmedetomidine, according to new research. Study investigators, who presented their results today at the 29th Annual Meeting of the American Academy of Pain Medicine, concluded that dexmedetomidine may be a new and effective treatment option for opioid-induced hyperalgesia (OIH).

12 Apr 2013

Nalmefene can provide important clinical benefit for alcohol-dependent patients

A potential new treatment for alcoholism called nalmefene is effective and safe for reducing alcohol consumption in alcohol dependent individuals, says a new study published this week in Biological Psychiatry.

12 Apr 2013

Migraine severity and adiponectin: an interview with Dr. B. Lee Peterlin, Johns Hopkins University School of Medicine

Migraine affects an estimated 30 million people in the U.S, with the one year prevalence of migraine estimated at 12% of the general population, including 18% of all women and 6% of all men.

12 Apr 2013

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.

12 Apr 2013

Ohio State researchers use smart phones to evaluate progress of stroke survivors

While many of us take the technology packed into smart phones and tablets for granted, researchers that specialize in rehabilitation are inspired by it, using it to evaluate the progress of stroke survivors who are learning to walk again.

10 Apr 2013

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis.

10 Apr 2013

REVEAL trial: VASCAZEN meets primary endpoint

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, is pleased to announce that VASCAZEN met its primary endpoint in the REVEAL trial.

10 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Antibiotic drug minocycline yields modest improvements in children with fragile X syndrome

The antibiotic drug minocycline yields "modest" but meaningful improvements in functioning and mood for children with fragile X syndrome (FXS), reports a study in the April Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics.

9 Apr 2013

Placebo News and Research

Flunisyn Phase 2a trial data shows positive results in elderly population

GlycoMimetics reports Phase 2 clinical study results of GMI-1070

COPD phase III study by Almirall and Forest Laboratories announces positive results

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

GTx to continue two pivotal Phase III clinical trials of enobosarm

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

L-carnitine improves cardiac health in patients after heart attack, say researchers

KYTHERA Biopharmaceuticals reports positive results from Phase IIb study of ATX-101

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

Two physicians receive Junior Investigator Recognition Awards at Internal Medicine 2013

Dexmedetomidine may be an effective treatment option for opioid-induced hyperalgesia

Nalmefene can provide important clinical benefit for alcohol-dependent patients

Migraine severity and adiponectin: an interview with Dr. B. Lee Peterlin, Johns Hopkins University School of Medicine

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Ohio State researchers use smart phones to evaluate progress of stroke survivors

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

REVEAL trial: VASCAZEN meets primary endpoint

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Antibiotic drug minocycline yields modest improvements in children with fragile X syndrome

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News